5 articles with StrideBio
StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Deborah D. Ascheim, M.D., to the newly created position of Chief Medical Officer.
3/17/2021Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.
- Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs - - Financing will also support organizational growth and GMP manufacturing expansion, building on the company's current 1000 liter scale in-house production process -
StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith as Chief Operating Officer. In this key position, Mr. Monteith will play a lead role in expanding the scale and breadth of StrideBio's operations, incl
Newly created role will oversee the translation of programs from research stage into the clinic